🫀 Comparable CV Benefits: Semaglutide Versus Tirzepatide in Real-World Practice

🔥 Main in 3 points

• Semaglutide and tirzepatide show similar cardiovascular outcomes when directly compared in real-world US cohorts of patients with T2D and high CV risk.
• Hazard ratio for MACE (myocardial infarction, stroke, or death): 1.06 (95% CI, 0.95–1.18) for tirzepatide versus semaglutide, indicating no significant difference.
• Absolute CV event rates were similar between both agents, complementing RCT evidence.

🧪 Context

Five cohort studies using insurance-based US data (2018–2025) among patients with obesity and/or T2D, emulating SUSTAIN-6 and SURPASS-CVOT trials, followed by head-to-head comparison, with propensity matching.

📍 Practical significance

• Choice between semaglutide and tirzepatide for CV risk reduction can be primarily individualized, as both yield comparable outcomes for MI, stroke, and all-cause mortality.
• Supports either agent in patients with T2D needing CV protection, allowing flexibility if access or tolerability is limiting.

🔗 PubMed | Nature Med (Full Text)

🫀 Semaglutide Significantly Reduces Incident Neurodegeneration in T2D: Large Real-World Analysis

🧪 What was studied

Retrospective multinational cohort (n=214,442) with T2D, comparing new initiation of GLP-1 RA (notably semaglutide, liraglutide, dulaglutide) vs DPP4 inhibitors or basal insulin, with 4-year mean follow-up. Primary: diagnosis of neurodegenerative disorders (Alzheimer’s, Parkinson’s, dementias).

📈 Key results

• GLP-1 RA group had lower risk of any neurodegeneration vs DPP4i: HR 0.81 (95% CI, 0.77–0.86)
• For semaglutide, HR for neurodegeneration was 0.75 (0.67–0.84), dementia 0.76 (0.72–0.81), AD 0.77 (0.68–0.87), Parkinson’s NS.
• Effects consistent regardless of sex, age, or comparator.

📍 What this changes in practice

• GLP-1 RAs, including semaglutide, are associated with a meaningful reduction in new neurodegenerative diagnoses in T2D.
• Supports discussion with T2D patients at higher neurologic risk; further study warranted, but provides a rationale for selecting GLP-1 RA over DPP4i/insulin when appropriate.

🔗 PubMed | Full Article

⚠️ Safety signal: Higher AKI Reporting Rate with Semaglutide vs Tirzepatide in Pharmacovigilance Study

🧪 Context

Analysis of FDA Adverse Event Reporting (FAERS, Jan 2022–Sep 2025): compared acute kidney injury (AKI) signal among tirzepatide (92,807 reports) and semaglutide (41,065 reports) initiators.

📊 Numbers

• AKI reports: tirzepatide 0.47%, semaglutide 1.07%
• Reporting odds ratio: tirzepatide vs semaglutide ROR 0.44 (95% CI, 0.38–0.50)

📍 Actions

• Remain vigilant for AKI with semaglutide, especially in at-risk (volume depleted, CKD) patients.
• Counsel on hydration and monitor renal function, especially on initiation/titration.
• Results may reflect reporting bias—do not preclude use, but underscore need for risk minimization.

🔗 PubMed | Journal Link

🫀 Real-World Effectiveness: Oral Semaglutide Lowers HbA1c + Weight in Indian T2D Cohort

🧪 What was studied

34–44 week multicenter, non-interventional study in India (n=388; 70.1% completed). Adults with T2D naïve to injectables started oral semaglutide.

📈 Key results

• Mean HbA1c reduction: −1.78% (CI: −1.88, −1.68), p<0.0001
• Mean weight loss: −7.2 kg (−7.8, −6.6), p<0.0001
• Greatest HbA1c drop in baseline HbA1c >9% group (−2.48%); 34.2% achieved HbA1c <7%.
• No new safety signals.

📍 What this changes in practice

• Oral semaglutide is effective for both A1c lowering and weight reduction in real-world Indian adults.
• Can be considered in T2D patients unwilling or unable to use injectables.
• Favorable in newly diagnosed or poorly controlled without injectable requirement.

🔗 PubMed | Journal Link

🫀 Semaglutide Enables Waitlisting and Transplantation for Obese Kidney Candidates

🧪 What was studied

Single-center, prospective cohort of 23 patients previously ineligible for renal transplant due to obesity. Pre-transplant SC semaglutide up to 1 mg/week; median 12.2 months’ follow-up.

📈 Key results

• Mean weight loss: –11.4 kg (p≤0.001), BMI –3.9 points, waist –9.6 cm.
• 56.5% of initially ineligible patients listed; 61.5% of those transplanted.
• No major side effects reported.

📍 What this changes in practice

• Semaglutide should be considered as a non-surgical strategy for weight optimization in CKD patients ineligible for transplant due to obesity.
• Can increase access to renal transplantation and may reduce need for bariatric surgery.
• Monitor for GI side effects; coordinate with transplant teams.

🔗 PubMed | Full Article

🫀 Semaglutide Shows Real-World Weight Loss and Metabolic Benefit in US VA Patients

🧪 What was studied

Retrospective review (n=201) at VA Medical Center; overweight/obese veterans on semaglutide for weight loss (Jan 2021–Jul 2023). Includes those with/without T2D.

📈 Key results

• Mean weight loss at 12 months: 11.5 kg (10.0% body weight), p<0.001.
• 74% lost ≥5%, 50% ≥10%, 24% ≥15%, 12% ≥20% body weight.
• SBP −3.4 mmHg, HbA1c −0.32%, TG −36 mg/dL, LDL-C −12 mg/dL at 12 months.
• Safety profile consistent with prior RCTs.

📍 What this changes in practice

• Supports semaglutide for weight management and metabolic risk reduction in veteran/multimorbid populations, beyond clinical trial settings.

🔗 PubMed | Journal Link

❤️ Semaglutide Lowers Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in T2D

🧪 What was studied

Retrospective cohort (n=1,212,775; T2D and overweight/obese, US Military Health System, 2017–2023), compared semaglutide vs. non-GLP-1 RA anti-diabetic therapies for NAION events.

📈 Key results

• T2D: semaglutide associated with lower NAION risk, OR 0.36 (95% CI 0.25–0.51) vs non-GLP-1 RAs.
• Overweight/obesity: no significant effect (OR 0.10, 95% CI 0.01–1.35).
• PDE5 inhibitor use also reduced NAION risk.

📍 What this changes in practice

• No evidence to support withholding semaglutide for fear of NAION in T2D.
• No apparent risk signal in overweight/obese non-diabetic cohort.

🔗 PubMed | Journal Link

🫀 Semaglutide Reduces Weight, Modestly Improves Cognition in MDD with Cognitive Dysfunction

🧪 What was studied

RCT (n=72, MDD with cognitive impairment, overweight/obese; 16 weeks’ oral semaglutide 14 mg vs placebo; double-blind).

📈 Key results

• No significant effect on executive function (primary).
• Improved global cognition (secondary, Z = 2.39, 95% CI 0.19–4.6, p=0.03).
• Weight loss: −6.0 kg (p<0.001), no effect on depressive symptoms or suicidality.
• GI side effects common; no serious AEs.

📍 What this changes in practice

• Adjunctive semaglutide is safe in MDD; may improve global cognitive outcomes and body weight.
• Useful off-label option for obese/overweight MDD patients, with counseling regarding GI AEs and limited effect on mood symptoms.

🔗 PubMed | Med (NY)

🧾 Semaglutide in Pediatric Obesity: Meta-Analysis

✅ Do

• Consider semaglutide or liraglutide for weight and BMI reduction in children with obesity; SMD at 12 months −0.41 (weight), −0.39 (BMI) vs control.
• Use for additional lowering of fasting glucose.

⚠️ With caution

• Monitor for GI side effects: increased risk of constipation (RR=3.98), nausea (RR=2.62), vomiting (RR=4.19), and abdominal pain (RR=1.65).

🚫 Avoid

• Over-reliance on pharmacotherapy without lifestyle support.

🔗 PubMed | Journal Link

🫀 Perioperative Semaglutide/GLP-1 RA Lowers Pseudoarthrosis in Spine Surgery

🧪 What was studied

Retrospective cohort, adults with long-segment (≥7-level) spinal deformity correction (2010–2024), GLP-1 RA use perioperatively vs matched controls.

📈 Key results

• Pseudoarthrosis risk reduced for GLP-1 RA users: RR 0.68–0.71 at 6m, 1y, 2y, 3y postop (all p<0.05).
• Lower hospital readmission (RR 0.86), sepsis (RR 0.49) at 90 days.
• No increased risk of perioperative complications.

📍 What this changes in practice

• Consider perioperative GLP-1 RA for metabolic patients undergoing complex spine surgery to reduce nonunion and readmission risk.

🔗 PubMed | Global Spine Journal

🫀 Adjunctive Semaglutide Post–Bariatric Surgery Boosts and Maintains Weight Loss

🧪 What was studied

Observational, 121 patients post–metabolic/bariatric surgery (various procedures) with weight regain/suboptimal loss, treated with naltrexone/bupropion (n=34), liraglutide (n=23), or semaglutide (n=64).

📈 Key results

• OMM associated with further weight loss: median 8.8% loss at median 9-month follow-up.
• Semaglutide most used (53%).
• Adverse events minor and as expected.

📍 What this changes in practice

• Strong support for GLP-1 RA use as routine adjuvant after MBS to address weight regain/suboptimal outcomes.
• Select semaglutide when weight regain is pronounced.

🔗 PubMed | Journal Link

🫀 Semaglutide Plus Intragastric Balloon: Optimal Weight Loss and Regain Prevention

🧪 What was studied

Prospective, randomized study (n=40): IGB vs IGB + semaglutide in adults (BMI ≥27), 12-month follow-up.

📈 Key results

• IGB + semaglutide: greater weight loss at 6mo (29.1 vs 18.4 kg), at 12mo (33.0 vs 15.6 kg), p<0.001 for both.
• Post–IGB removal: IGB only group regained weight; IGB + semaglutide group continued to lose weight.

📍 What this changes in practice

• Add semaglutide to IGB therapy for more durable and greater weight loss in patients electing non-surgical obesity therapies.

🔗 PubMed | Obesity Surgery

🧪 Semaglutide May Reduce Onset of Neurodegeneration in T2D—Mechanistic Considerations

✅ Do

• Prefer GLP-1 RA, including semaglutide, if neuroprotective benefit is desired in patients with T2D at risk for dementia or neurodegeneration.

⚠️ With caution

• Do not extrapolate these findings to nondiabetic populations or as a primary neuroprotective strategy pending RCT evidence.

🔗 PubMed | Full Article

🫀 Mechanistic Renal Trial for Semaglutide: The REMODEL Study Framework

🧪 What was studied

Multi-modal mechanistic trial design combining fMRI, kidney biopsy, and biomarker profiling to elucidate semaglutide’s nephroprotective mechanisms in CKD (building on FLOW trial clinical benefits).

📍 What this changes in practice

• While clinical use unchanged, supports deeper biomarker and imaging work-up for select patients, and research participation for those interested.

🔗 PubMed | Kidney International